Hongchuang Xu

Peking University

Papers

1

Total Citations

15

H-Index

1

About

Hongchuang Xu is a pioneering researcher at the intersection of molecular imaging and urologic oncology, whose work has significantly advanced the field of prostate cancer diagnostics and surgery. His primary research focuses on the development and clinical translation of dual-modality imaging probes, particularly those targeting prostate-specific membrane antigen (PSMA). Xu’s major contribution lies in the first-in-human study of a PSMA-targeted probe that seamlessly integrates preoperative positron emission tomography/computed tomography (PET/CT) with intraoperative fluorescence imaging. This groundbreaking work, published in 2025 and already garnering 15 citations, demonstrates the potential to improve surgical precision by enabling real-time tumor visualization during prostatectomy. By bridging the gap between diagnostic imaging and surgical guidance, Xu’s research addresses a critical need in personalized cancer care. His achievements highlight a commitment to translating bench-side innovations into clinical practice, offering a tangible pathway to reduce positive surgical margins and enhance patient outcomes. For students and researchers, Xu’s work exemplifies the power of interdisciplinary collaboration in tackling complex oncological challenges.

Research Focus

Key Achievements

1
H-Index
1
Papers
15
Total Citations
15
Avg Citations/Paper
🏆 Most Cited Paper
First-in-human Study of a Dual-modality Prostate-specific Membrane Antigen–targeted Probe for Preoperative Positron Emission Tomography/Computed Tomography Imaging and Intraoperative Fluorescence Imaging in Prostate Cancer
15 citations · 2025
📈 Most Prolific Year: 2025 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: Peking University

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago